Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Open-label Study of the Absorption, Metabolism, and Excretion of Poziotinib Following a Single Oral Dose of [14C]-Poziotinib in Healthy Male Subjects

NCT04436562 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT04436562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04436562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Open-label Study of the Absorption, Metabolism, and Excretion of Poziotinib Following a Single Oral Dose of [14C]-Poziotinib in Healthy Male Subjects
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 1
Overall status
Completed
Start date
May 29, 2020
Completion date
July 17, 2020
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy